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Does Fractional Blistergrafting Improve
Degree Burn Wound Healing and Scar Outcome without a
Significant Donor Site?
Cassandra Pinataro, Sigrid Blome-Eberwein MD

Introduction

Lehigh Valley Health Network, Allentown, Pennsylvania

Results

Results

• Vancouver Scar Scale (most widely used scar evaluation
scale 1-15 but not sensitive enough for this study)
– Readings at a max of 2/15 with normal vascularity,
pliability, and height, and 2 patients showing mixed
pigmentation in skin sites.
• Treatment site healed with less complications and
pigmentation changes than the acellular site according to
observation.
• The Patient Observer Scar Scale (more reliable scars scale
1-10)
– Readings showed Cellutome™️ blister graft patients to
have pain and stiffness reaching a maximum of 2/10,
itching reaching a maximum of 3/10, scar coloring at a
maximum of 5/10, and thickness at a maximum of
4/10.
• P-Value shows the findings to be statistically insignificant,
observations showed that the Cellutome™️ blister graft site
healed better than the acellular site.

• Split-thickness skin grafting & acellular treatment have
complications including overgrafting, hypertrophic scarring
and pigmentation changes in burn patients.
• Cellutome™️ blister grafts may aid in re-pigmentation,
minimized donor site, decreased hypertrophic scarring, and
minimized pain.

All of the patients in this study showed a 100% treatment success rate with no
infection, failed grafts, or STSG needed.

Purpose
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Determine if:
1. Healing occurs faster than acellular treatment (within 21
days of treatment) in 2nd degree burn wounds
2. Pigment changes are decreased using Cellutome™️ blister
grafts.
3. Donor site is not noticeable with this technique.
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Figure 2

Overall, the Cellutome™️ blister graft treatment was faster than
acellular treatment.

Methods
• Prospective controlled study comparing acellular to cellular
technique in 2nd degree burn wound healing.
• IRB approval and informed consent obtained.
• Cellutome™️ harvester creates small blisters which are cut
and adhered to transfer medium which is applied to the
treatment site.
• SuprathelⓇ temporary skin substitute used as dressing until
healing.
• Donor site covered with silicone tape.
• Follow-up data was obtained up to 1 year +/- 6months posttreatment
• Days until healing, pigmentation, sensation, Vancouver Scar
Scale and POSAS recorded.

Conclusion
Figure 3

Figure 3 and 4 show the erythema and melanin levels in the skin sites after Cellutome™️ blister
grafting. The treatment site shows less variation from the healthy site than the acellular site.
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Figure 1
The A site received Cellutome™️ blister grafts and the B site received acellular treatment. Notice the small
dots of pigmentation on the healed A site. These will continue to regenerate pigmented skin cells as the skin
heals to give the A site an appearance closer to that of the surrounding healthy skin.
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1. The Semmes-Weinstein Scale should not have different readings since nerve
endings were not damaged. Filaments in the test may have missed nerves on
some of the readings due to location.
2. The P-Values do not show statistical significance, but this is due to the small
data set. Few patients are willing to return to the office for additional checkups
throughout the study. Patients had a faster healing and less pigmented scar with
no donor site using Cellutome™️ blister grafting.
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• The Cellutome™️ blister grafts met the first endpoint of this
study
– Healing time of 18 days or less (faster than the
acellular control site)
• Microscopic donor sites did not bother the patients.
• Treatment site had sensation and appearance comparable to
that of healthy skin (second study endpoint)
• Cellutome™️ blister grafts should be further explored as:
– An effective and efficient method of epidermal skin
grafting
– Having a low rate of complication and a high rate of
satisfaction
– An alternative to acellular treatment in 2nd degree
(partial thickness) burn patients to avoid pigment
changes and hypertrophic scarring.
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